Enforcement Report - Week of June 19, 2024
Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Docetaxel Injection
SCHAUMBURG, Ill., May 28, 2024 /PRNewswire/ -- Sagent Pharmaceuticals today announced the voluntary nationwide recall of two lots of Docetaxel Injection, USP (80 mg per 8 mL multi-dose vials and 160 mg per 16 mL multi-dose vials). The product was distributed by Sagent Pharmaceuticals. Sagent has initiated this voluntary recall of Docetaxel Injection, USP to the User Level as the result of a customer complaint due to potential presence of particulate matter from the stopper in the drug product.
Enforcement Report - Week of May 22, 2024
Sagent's Generic Cyclophosphamide Receives Approval in the U.S.
Enforcement Report - Week of May 31, 2023
Enforcement Report - Week of March 15, 2023
Sagent Pharmaceuticals, Inc. Receives FDA Warning Letter
Sagent's Generic Cyanocobalamin Receives Approval in the U.S.